Principal component analysis of the oxidative stress, inflammation, and dyslipidemia influence in patients with different levels of glucoregulation
Oxidative stress in (pre)diabetes
Abstract
Objective: The aim of the study was to explore the mutual relationship between oxidative stress, inflammation and metabolic biomarkers in subjects with prediabetes (PRE), newly diagnosed type 2 diabetes patients (NT2D) and overt type 2 diabetes (T2D) using principal component analysis (PCA) as a thorough statistical approach.
Patients and Methods: Glycated hemoglobin, lipid parameters, inflammation (IL-6, CRP and fibrinogen) and oxidative stress markers [pro-oxidants (AOPP, PAB, TOS) and antioxidants (PON1, tSHG, TAS)] were measured. PCA was applied to explore the factors most strongly influencing glucoregulation.
Results: A total of 278 subjects were enrolled: 37 PRE, 42 NT2D and 99 T2D, who were compared with 100 healthy subjects as a control group (CG). PCA emphasized 4 different factors explaining 49% of the variance of the tested parameters: Oxidative stress-Dyslipidemia related factor (with positive loading of TG and tSHG, and with negative loading of HDL-c and TAS), Dyslipidemia related factor (i.e., total cholesterol and LDL-c, both with positive loading), Anthropometric related factor (i.e., waist and hip circumference, both with positive loading) and Oxidative stress-Inflammation related factor (i.e., PAB, fibrinogen, and CRP, all with positive loading). Out of these 4 factors, only Oxidative stress – Dyslipidemia related factor showed a significant predictive capability towards poor glucoregulation. An increase in this factor by one unit showed a 1.6 times higher probability for poor glucoregulation.
Conclusion: Redox disbalance (determined with lower TAS and higher tSHG), in addition to higher TG and lower HDL-c were associated with poor glucoregulation.
Copyright (c) 2022 Aleksandra Klisic
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.